GHO Capital Acquires X‑Chem, Inc.

X-Chem Acquires IntelliSyn and AviSyn to Expand Drug Discovery Services

January 26, 2021

Biotechnology

X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.

X-Chem Acquires Glamorous AI

October 28, 2021

Biotechnology

X-Chem, a leader in DNA-encoded library (DEL) technology, has acquired Glamorous AI, an AI-driven drug discovery software provider. The deal combines X-Chem's large DEL datasets with Glamorous AI's RosalindAI platform to accelerate early-stage small-molecule drug discovery and expand X-Chem's machine-learning capabilities.

X-Chem Acquires Glamorous AI and ComInnex

October 29, 2021

Biotechnology

X-Chem, a GHO Capital-backed leader in DNA-encoded library (DEL) technology, has acquired AI drug-discovery specialist Glamorous AI and Budapest-based synthetic chemistry services provider ComInnex. The deals expand X-Chem’s machine-learning capabilities and synthetic chemistry capacity, broadening its global footprint and accelerating small-molecule discovery services for biopharma clients.

GHO Capital Partners Acquires Scientist.com

November 20, 2025

Cloud & SaaS

GHO Capital Partners has completed the acquisition of Scientist.com, an AI-enabled R&D orchestration platform for the life sciences industry. The deal (terms undisclosed) will support Scientist.com's expansion of AI-driven capabilities and international growth while the company remains led by its existing management team in Solana Beach, California.

GHO Capital Invests in RoslinCT

January 11, 2022

Biotechnology

GHO Capital Partners LLP has made a growth equity investment in RoslinCT, a UK-based contract development and manufacturing organisation (CDMO) focused on advanced cell therapies. The capital will support scaling of RoslinCT’s cGMP manufacturing capacity, international customer acquisition and product diversification to drive commercial-scale cell therapy manufacturing.

GHO Capital and Partners Group Invest in Sterling Pharma Solutions

May 25, 2023

Pharmaceuticals

GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.